| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/15/2023 | 25.6% | UBS | $4.6 → $5.2 | Maintains | Buy |
| 06/29/2023 | 93.24% | B of A Securities | $14 → $8 | Maintains | Buy |
| 06/26/2023 | 44.93% | Morgan Stanley | $6 → $6 | Reiterates | Equal-Weight → Equal-Weight |
| 06/20/2023 | 44.93% | Morgan Stanley | → $6 | Reiterates | → Equal-Weight |
| 06/14/2023 | -3.38% | Jefferies | $19 → $4 | Downgrades | Buy → Hold |
| 04/20/2023 | 69.08% | Societe Generale | → $7 | Downgrades | Buy → Hold |
| 04/20/2023 | 44.93% | Morgan Stanley | $9 → $6 | Maintains | Equal-Weight |
| 04/19/2023 | 69.08% | JP Morgan | $9 → $7 | Downgrades | Overweight → Neutral |
| 04/06/2023 | 141.55% | UBS | $14 → $10 | Maintains | Buy |
| 03/16/2023 | 69.08% | TD Cowen | $13 → $7 | Downgrades | Outperform → Market Perform |
| 01/18/2023 | 117.39% | Morgan Stanley | $10 → $9 | Maintains | Equal-Weight |
| 10/25/2022 | 141.55% | Morgan Stanley | $12 → $10 | Maintains | Equal-Weight |
| 09/20/2022 | 286.47% | UBS | $14 → $16 | Maintains | Buy |
| 09/16/2022 | 310.63% | Cowen & Co. | $22 → $17 | Maintains | Outperform |
| 09/16/2022 | 189.86% | Morgan Stanley | $14 → $12 | Maintains | Equal-Weight |
| 09/16/2022 | 262.32% | Credit Suisse | $16 → $15 | Maintains | Outperform |
| 05/16/2022 | 262.32% | JP Morgan | $23 → $15 | Maintains | Overweight |
| 04/12/2022 | 238.16% | Morgan Stanley | $39 → $14 | Downgrades | Overweight → Equal-Weight |
| 03/24/2022 | — | UBS | Upgrades | Neutral → Buy | |
| 03/18/2022 | 455.56% | JP Morgan | $34 → $23 | Maintains | Overweight |
| 03/16/2022 | 334.78% | Credit Suisse | $27 → $18 | Maintains | Outperform |
| 02/17/2022 | 552.17% | Credit Suisse | $35 → $27 | Maintains | Outperform |
| 01/04/2022 | 721.26% | JP Morgan | $40 → $34 | Maintains | Overweight |
| 10/14/2021 | 672.95% | B of A Securities | $20 → $32 | Upgrades | Underperform → Buy |
| 09/15/2021 | 914.49% | Morgan Stanley | $40 → $42 | Maintains | Overweight |
| 09/15/2021 | 745.41% | Credit Suisse | $43 → $35 | Maintains | Outperform |
| 08/17/2021 | 866.18% | Morgan Stanley | $42 → $40 | Maintains | Overweight |
| 05/19/2021 | 914.49% | Morgan Stanley | $37 → $42 | Maintains | Overweight |
| 02/17/2021 | 793.72% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
| 02/16/2021 | 793.72% | Jefferies | → $37 | Initiates Coverage On | → Buy |
| 02/16/2021 | 793.72% | Morgan Stanley | → $37 | Initiates Coverage On | → Overweight |
What is the target price for MYT Netherlands Parent (MYTE)?
The latest price target for MYT Netherlands Parent (NYSE: MYTE) was reported by UBS on September 15, 2023. The analyst firm set a price target for $5.20 expecting MYTE to rise to within 12 months (a possible 25.60% upside). 16 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for MYT Netherlands Parent (MYTE)?
The latest analyst rating for MYT Netherlands Parent (NYSE: MYTE) was provided by UBS, and MYT Netherlands Parent maintained their buy rating.
When is the next analyst rating going to be posted or updated for MYT Netherlands Parent (MYTE)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of MYT Netherlands Parent, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for MYT Netherlands Parent was filed on September 15, 2023 so you should expect the next rating to be made available sometime around September 15, 2024.
Is the Analyst Rating MYT Netherlands Parent (MYTE) correct?
While ratings are subjective and will change, the latest MYT Netherlands Parent (MYTE) rating was a maintained with a price target of $4.60 to $5.20. The current price MYT Netherlands Parent (MYTE) is trading at is $4.14, which is out of the analyst's predicted range.